Enhancement without a rationale? Black pepper extract (piperine) in dietary supplements and the future of formulation: a perspective from Japan
- 1KYB Medical Service Co., Ltd. , ,
Abstract
Bioavailability enhancers, most notably black pepper extract (piperine), are increasingly added to dietary supplements with claims of “improved absorption.” Piperine raises systemic exposure to co-administered compounds not by enhancing absorption but mainly by inhibiting drug-metabolizing systems, including CYP3A4, CYP2C9, and P-glycoprotein, and can therefore alter concentrations of concomitant medications, including drugs with a narrow therapeutic index. This Perspective argues that piperine is frequently included in multi-ingredient products without a defensible formulation rationale and, in the author's observation, now appears in Japan's practitioner-exclusive (clinic-dispensed) supplement market. A structured summary of 22 human pharmacokinetic studies shows that reports of enhanced nutrient absorption derive from manufacturer-affiliated studies of a few chemical forms; that trials without piperine-manufacturer involvement have not confirmed enhancement for curcumin or resveratrol at supplement doses; and that interaction studies with prescription drugs, mostly from groups with no commercial interest, repeatedly demonstrate altered drug exposure. This asymmetry is compounded by inadvertent supplement–supplement combinations and reports of turmeric–piperine-associated liver injury. The conditions under which piperine is a rational formulation choice are defined, and label warnings are endorsed as necessary but insufficient. “Practitioner-exclusive” labeling does not guarantee a sound formulation, and the good manufacturing practice requirements mandatory for Foods with Function Claims in Japan since September 2026 address manufacturing quality, not formulation appropriateness. Supplement formulation should be a deliberate, expert-driven discipline rather than an accumulation of trending ingredients; formulation rationale and interaction risk, not manufacturing quality alone, should become explicit considerations for clinicians, regulators, and industry.
Related
- Microwave-induced in situ amorphization: mechanistic basis, formulation principles, and translational perspective
- Impact of polyherbal formulation on cognitive functions in a scopolamine-induced cognitive impairment model: a spatial memory and learning perspective
- Piperine attenuated CoCl2-induced oxidative stress and cellular injury in TM3 Leydig cells
- Synthesis, characterization, and in vitro activity of piperine nanocrystals against protoscoleces of Echinococcus granulosus.
- Neutrophil activation, antioxidant supplements and exercise-induced oxidative stress
BibTeX
@article{kaneko2026enhancement,
title = {{Enhancement without a rationale? Black pepper extract (piperine) in dietary supplements and the future of formulation: a perspective from Japan}},
author = {Masaki Kaneko},
journal = {Frontiers in nutrition},
year = {2026},
month = oct,
doi = {10.3389/fnut.2026.1981406},
url = {https://europepmc.org/article/PMC/PMC13719291},
note = {CC BY},
}
RIS
TY - JOUR
TI - Enhancement without a rationale? Black pepper extract (piperine) in dietary supplements and the future of formulation: a perspective from Japan
AU - Masaki Kaneko
PY - 2026
DA - 2026/10/16
JO - Frontiers in nutrition
DO - 10.3389/fnut.2026.1981406
UR - https://europepmc.org/article/PMC/PMC13719291
AB - Bioavailability enhancers, most notably black pepper extract (piperine), are increasingly added to dietary supplements with claims of “improved absorption.” Piperine raises systemic exposure to co-administered compounds not by enhancing absorption but mainly by inhibiting drug-metabolizing systems, including CYP3A4, CYP2C9, and P-glycoprotein, and can therefore alter concentrations of concomitant medications, including drugs with a narrow therapeutic index. This Perspective argues that piperine is frequently included in multi-ingredient products without a defensible formulation rationale and, in the author's observation, now appears in Japan's practitioner-exclusive (clinic-dispensed) supplement market. A structured summary of 22 human pharmacokinetic studies shows that reports of enhanced nutrient absorption derive from manufacturer-affiliated studies of a few chemical forms; that trials without piperine-manufacturer involvement have not confirmed enhancement for curcumin or resveratrol at supplement doses; and that interaction studies with prescription drugs, mostly from groups with no commercial interest, repeatedly demonstrate altered drug exposure. This asymmetry is compounded by inadvertent supplement–supplement combinations and reports of turmeric–piperine-associated liver injury. The conditions under which piperine is a rational formulation choice are defined, and label warnings are endorsed as necessary but insufficient. “Practitioner-exclusive” labeling does not guarantee a sound formulation, and the good manufacturing practice requirements mandatory for Foods with Function Claims in Japan since September 2026 address manufacturing quality, not formulation appropriateness. Supplement formulation should be a deliberate, expert-driven discipline rather than an accumulation of trending ingredients; formulation rationale and interaction risk, not manufacturing quality alone, should become explicit considerations for clinicians, regulators, and industry.
SN - 2296-861X
ER -